Keywords: EMEA, Tysabri, Elan, Biogen, GlaxoSmithKline, Arepanrix, Arzerra, Flu vaccines, Tamiflu

EMEA proposes measures to better manage Tysabri’s PML risks; positive opinions from CHMP include two on GSK products

Article | 22 January 2010

The European Medicines Agency (EMEA) has finalized a review of Tysabri (natalizumab) and the risk of progressive multifocal leukoencephalopathy (PML), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in